- Home
- CLST vs OTLK Comparison
CLST vs OTLK Comparison
Compare CLST & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLST
- OTLK
- Stock Information
- Founded
- CLST 1922
- OTLK 2010
- Country
- CLST United States
- OTLK United States
- Employees
- CLST N/A
- OTLK N/A
- Industry
- CLST
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLST
- OTLK Health Care
- Exchange
- CLST Nasdaq
- OTLK Nasdaq
- Market Cap
- CLST 51.4M
- OTLK 48.3M
- IPO Year
- CLST N/A
- OTLK 2016
- Fundamental
- Price
- CLST $12.23
- OTLK $1.71
- Analyst Decision
- CLST
- OTLK Strong Buy
- Analyst Count
- CLST 0
- OTLK 5
- Target Price
- CLST N/A
- OTLK $9.60
- AVG Volume (30 Days)
- CLST 5.8K
- OTLK 819.5K
- Earning Date
- CLST 07-30-2025
- OTLK 08-13-2025
- Dividend Yield
- CLST N/A
- OTLK N/A
- EPS Growth
- CLST N/A
- OTLK N/A
- EPS
- CLST 0.57
- OTLK 0.83
- Revenue
- CLST $11,257,000.00
- OTLK N/A
- Revenue This Year
- CLST N/A
- OTLK N/A
- Revenue Next Year
- CLST N/A
- OTLK $379.84
- P/E Ratio
- CLST $22.11
- OTLK $2.07
- Revenue Growth
- CLST 200.91
- OTLK N/A
- 52 Week Low
- CLST $10.67
- OTLK $0.87
- 52 Week High
- CLST $12.56
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- CLST 57.11
- OTLK 46.49
- Support Level
- CLST $11.91
- OTLK $1.65
- Resistance Level
- CLST $12.56
- OTLK $1.97
- Average True Range (ATR)
- CLST 0.19
- OTLK 0.12
- MACD
- CLST 0.03
- OTLK -0.03
- Stochastic Oscillator
- CLST 59.26
- OTLK 10.94
About CLST Catalyst Bancorp Inc.
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.